このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.

2026年11月10日 更新者:Sanofi

A Nested Phase 3, Randomized, Active-controlled, Open-label, 2-arm, Multicenter Study to Investigate the Immunogenicity and Safety of Sanofi's Hexavalent DTaP-IPV-HB-PRP~T Combined Vaccine Given at 2, 4, and 6 Months of Age Compared With DTaP-IPV//PRP~T Combined Vaccine (Pentaxim™) Given at 2, 4, and 6 Months of Age Administered With a Monovalent Hepatitis B Vaccine Given at 1 and 6 Months of Age to Healthy Chinese Infants Who Previously Received a Birth Dose of Monovalent Hepatitis B Vaccine

The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers.

Study details include:

  • The study duration per participant will be approximately 18 months.
  • The study vaccines administration:
  • Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA.
  • Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.

調査の概要

研究の種類

介入

入学 (推定)

720

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Trial Transparency email recommended (Toll free for US & Canada)
  • 電話番号:option 6 800-633-1610
  • メール:Contact-US@sanofi.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1ヶ月~1ヶ月 (子)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine
  • Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, and in both cases medically stable as assessed by the investigator
  • Participants who are born to mothers with documented HBsAg seronegative status
  • Informed consent form has been signed and dated by the parent(s) or other LAR
  • Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures

Exclusion Criteria:

  • Known/suspected immunodeficiency; immunosuppressive therapy since birth; long-term systemic corticosteroid therapy
  • History of diagnosis of Hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection
  • History of seizure or significant stable or progressive neurological disorders
  • Known systemic hypersensitivity to any study intervention components, or history of a life-threatening reaction to study interventions or product with the same substances
  • Known thrombocytopenia
  • Bleeding disorder
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Any vaccine given since birth or planned receipt of any vaccine until 1 month after the completion of the primary series vaccination with the study interventions except for Bacille Calmette-Guérin (BCG) vaccine and meningococcal polysaccharide vaccine-A.
  • Previous vaccination against D, T, pertussis, poliomyelitis, Hep B (except the dose of Hep B given at birth) or Haemophilus influenzae type b infections (since birth) with an investigational or marketed vaccine.
  • Receipt of immune globulins, blood or blood-derived products
  • Participation in another clinical study for a vaccine, drug, medical device, or medical procedure at the time of study enrollment or planned participation during the present study period.
  • Known personal or maternal history of HIV or HCV seropositivity
  • Being in an emergency setting
  • Identified as a natural or adopted child of the Investigator/study site employee with direct involvement in the study

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group 1 (the investigational group)

Hexaxim at 2, 4 and 6 MoA

Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection

アクティブコンパレータ:Group 2 (the comparator group)

Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA

Pharmaceutical form:Freeze-dried PRP~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection

Pharmaceutical form: Depending on the brand procured Route of administration:IM injection

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
時間枠:Day181

Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA

Day181

二次結果の測定

結果測定
メジャーの説明
時間枠
Baseline, pre-vaccination sample
時間枠:Day 31

Ab concentrations/titers for each Ag

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 μg/mL
  • Anti-Hep B Ab concentrations ≥10 mIU/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
Day 31
1 month after the last dose of primary series:
時間枠:Day181

Ab concentrations/titers for each Ag

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 μg/mL and ≥1.0 μg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
  • Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL Ab individual concentration/titer ratios for all antigens except for Hep B) (post-Dose 3/pre-Dose 1) Anti-Hep B Ab individual concentration ratio (post-Dose 4 Hep B/pre-Dose 2 Hep B in the investigational group, or post-Dose 3 Hep B/post-Dose 2 Hep B in the comparator group) Note: Dose 1 Hep B corresponds to the dose of Hep B vaccine given at birth.
Day181
Before the booster dose:
時間枠:Day 511

Ab concentrations/titers for each

Ag of Pentaxim and Hep B Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
  • Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL
Day 511
1 month after the booster dose:
時間枠:Day 541

Ab concentrations/titers for each Ag of Pentaxim

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Seroconversion for anti-PT and anti-FHA defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Booster to post-Booster Ab individual concentration/titer ratios for all antigens (post-Booster/pre-Booster)
Day 541
Presence of immediate unsolicited adverse events (AEs)
時間枠:30 minutes after each and any vaccination
30 minutes after each and any vaccination
Presence of solicited injection site reactions
時間枠:for 8 days, including the day of each and any vaccination

(pre-listed in the participant diary and case report form [CRF])

for 8 days, including the day of each and any vaccination
Presence of solicited systemic reactions
時間枠:for 8 days, including the day of each and any vaccination

(pre-listed in the participant diary and CRF)

for 8 days, including the day of each and any vaccination
Presence of unsolicited AEs
時間枠:for 30 days, including the day of each and any vaccination
for 30 days, including the day of each and any vaccination
Presence of serious adverse events (SAEs)
時間枠:up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
Presence of related SAEs and fatal case regardless of causality
時間枠:Day 541
Day 541
Presence of AEs leading to study discontinuation
時間枠:Day 541
Day 541

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月28日

一次修了 (推定)

2028年4月27日

研究の完了 (推定)

2029年7月30日

試験登録日

最初に提出

2026年11月10日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • A3L00054
  • U1111-1227-3420 (レジストリ識別子:ICTRP)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する